ADMA Biologics (NASDAQ:ADMA) Announces Quarterly Earnings Results, Misses Expectations By $0.02 EPS

ADMA Biologics (NASDAQ:ADMAGet Rating) posted its earnings results on Wednesday. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.02), Fidelity Earnings reports. ADMA Biologics had a negative return on equity of 61.23% and a negative net margin of 88.51%. During the same period last year, the business earned ($0.16) EPS.

ADMA traded up $0.07 during trading on Friday, hitting $1.75. The company’s stock had a trading volume of 28,242 shares, compared to its average volume of 2,505,526. The business’s fifty day simple moving average is $1.83 and its 200 day simple moving average is $1.57. ADMA Biologics has a twelve month low of $1.01 and a twelve month high of $2.16. The company has a quick ratio of 2.77, a current ratio of 6.87 and a debt-to-equity ratio of 0.72.

Several analysts recently commented on ADMA shares. Zacks Investment Research raised ADMA Biologics from a “sell” rating to a “hold” rating in a report on Wednesday, May 4th. StockNews.com started coverage on ADMA Biologics in a report on Thursday, March 31st. They issued a “sell” rating on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, ADMA Biologics has a consensus rating of “Buy” and an average price target of $5.00.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. lifted its position in shares of ADMA Biologics by 0.8% in the first quarter. BlackRock Inc. now owns 4,107,382 shares of the biotechnology company’s stock valued at $7,517,000 after acquiring an additional 31,791 shares in the last quarter. Bank of Montreal Can purchased a new position in ADMA Biologics during the first quarter worth approximately $1,665,000. Bank of New York Mellon Corp lifted its position in ADMA Biologics by 79.6% during the first quarter. Bank of New York Mellon Corp now owns 83,401 shares of the biotechnology company’s stock worth $153,000 after buying an additional 36,967 shares in the last quarter. Raymond James & Associates lifted its position in ADMA Biologics by 24.0% during the first quarter. Raymond James & Associates now owns 199,984 shares of the biotechnology company’s stock worth $366,000 after buying an additional 38,715 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in ADMA Biologics by 360.0% during the first quarter. JPMorgan Chase & Co. now owns 79,106 shares of the biotechnology company’s stock worth $144,000 after buying an additional 61,909 shares in the last quarter. Institutional investors and hedge funds own 55.15% of the company’s stock.

ADMA Biologics Company Profile (Get Rating)

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Featured Stories

Earnings History for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.